新风胶囊对类风湿关节炎患者的临床疗效及血管内皮生长因子、肿瘤坏死因子-α的影响

The clinical effect of the Xinfeng capsule on rheumatoid arthritis and vascular endothelial growth factor and tumor necrosis factor-α levels

目的:观察新风胶囊对类风湿关节炎(Rheumatoid Arthritis,RA)患者的临床疗效及血管内皮生长因子(Vascular Endothelial Growth Factor,VEGF)、肿瘤坏死因子-α(Tumor Necrosis Factor-α,TNF-α)的影响。方法:将60例RA患者随机分为对照组和治疗组,对照组口服来氟米特,治疗组口服新风胶囊,治疗周期为4周。对比两组患者治疗前后的临床疗效、关节疼痛视觉模拟评分(Visual Analogue Scale,VAS)、简化的疾病活动度指标(Simplified Disease Activity Index,SDAI)及临床疾病活动度指标(Clinical Disease Activity Index,CDAI)、实验室指标[C反应蛋白(C-reactive Protein,CRP)、红细胞沉降率(Erythrocyte Sedimentation Rate,ESR)、类风湿因子(Rheumatoid Factor,RF)、抗环瓜氨酸肽抗体(Anti-cyclic Citrullinated Peptide Antibody,CCP-AB)、免疫球蛋白G(Immunoglobulin G,IgG)]的变化,同时检测血清VEGF、TNF-α的水平,并观察治疗过程中的出现的所有不良反应。结果:治疗后相比,治疗组总有效率明显优于对照组,两组的差异有统计学意义(P<0.05)。两组患者治疗后VAS、SDAI和CDAI评分,CRP、ESR、RF、CCP-AB、VEGF、TNF-α水平均下降,两组的差异有统计学意义(P<0.01),且治疗组在降低ESR、VAS、SDAI、CDAI、VEGF、TNF-α方面明显优于对照组(P<0.01,P<0.05)。结论:新风胶囊可有效缓解RA的临床症状,可能与降低VEGF、TNF-α水平,改善关节血管新生有关。

Objective:To observe the clinical efficacy of the Xinfeng capsules(新风胶囊)on RA and VEGF and TNF-αlevels.Methods:60 cases were randomly divided into the control group and the treatment group.The control group was given leflunomide orally,and the treatment group was given the Xinfeng capsules,for 4 weeks.Results:The total efficiency in the treatment group was significantly better than the control group(P<0.05).The VAS,SDAI and CDAI scores,CRP,ESR,RF,CCP-AB,VEGF,and TNF-αlevels in the two groups were decreased(P<0.01),and the treatment group showed obviously better effect than the control group in decreasing ESR,VAS,SDAI,CDAI,VEGF,and TNF-αlevels(P<0.01,P<0.05).Conclusion:The Xinfeng capsules can effectively relieve the clinical symptoms,which may be related to the reduction of VEGF and TNF-αlevels and the improvement of joint angiogenesis.